|
US6875584B1
(en)
*
|
1999-03-02 |
2005-04-05 |
University Of Georgia Research Foundation, Inc. |
Prophylactic and therapeutic immunization against protozoan infection and disease
|
|
US7534866B2
(en)
|
2005-10-19 |
2009-05-19 |
Ibc Pharmaceuticals, Inc. |
Methods and compositions for generating bioactive assemblies of increased complexity and uses
|
|
US7666400B2
(en)
*
|
2005-04-06 |
2010-02-23 |
Ibc Pharmaceuticals, Inc. |
PEGylation by the dock and lock (DNL) technique
|
|
US7550143B2
(en)
*
|
2005-04-06 |
2009-06-23 |
Ibc Pharmaceuticals, Inc. |
Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses
|
|
US7527787B2
(en)
*
|
2005-10-19 |
2009-05-05 |
Ibc Pharmaceuticals, Inc. |
Multivalent immunoglobulin-based bioactive assemblies
|
|
US7591994B2
(en)
|
2002-12-13 |
2009-09-22 |
Immunomedics, Inc. |
Camptothecin-binding moiety conjugates
|
|
US20160279239A1
(en)
|
2011-05-02 |
2016-09-29 |
Immunomedics, Inc. |
Subcutaneous administration of anti-cd74 antibody for systemic lupus erythematosus and autoimmune disease
|
|
CN1649902B
(zh)
*
|
2002-03-01 |
2011-04-13 |
免疫医疗公司 |
内在化抗-cd74抗体和使用方法
|
|
US7906118B2
(en)
|
2005-04-06 |
2011-03-15 |
Ibc Pharmaceuticals, Inc. |
Modular method to prepare tetrameric cytokines with improved pharmacokinetics by the dock-and-lock (DNL) technology
|
|
US7597876B2
(en)
*
|
2007-01-11 |
2009-10-06 |
Immunomedics, Inc. |
Methods and compositions for improved F-18 labeling of proteins, peptides and other molecules
|
|
US7563433B2
(en)
*
|
2007-01-11 |
2009-07-21 |
Immunomedics, Inc. |
Methods and compositions for F-18 labeling of proteins, peptides and other molecules
|
|
US7993626B2
(en)
|
2007-01-11 |
2011-08-09 |
Immunomedics, Inc. |
Methods and compositions for F-18 labeling of proteins, peptides and other molecules
|
|
US7651689B2
(en)
*
|
2002-11-15 |
2010-01-26 |
Albert Einstein College Of Medicine Of Yeshiva University |
Methods of applying ionization radiation for therapy of infections
|
|
AU2004213752B2
(en)
*
|
2003-01-31 |
2008-10-23 |
Immunomedics, Inc. |
Methods and compositions for administering therapeutic and diagnostic agents
|
|
US20170088635A1
(en)
*
|
2004-02-13 |
2017-03-30 |
Ibc Pharmaceuticals, Inc. |
Dock-and-Lock (DNL) Complexes for Therapeutic and Diagnostic Use
|
|
US8034352B2
(en)
|
2005-04-06 |
2011-10-11 |
Ibc Pharmaceuticals, Inc. |
Tetrameric cytokines with improved biological activity
|
|
US9481878B2
(en)
|
2004-02-13 |
2016-11-01 |
Immunomedics, Inc. |
Compositions and methods of use of immunotoxins comprising ranpirnase (Rap) show potent cytotoxic activity
|
|
US8491914B2
(en)
|
2004-02-13 |
2013-07-23 |
Ibc Pharmaceuticals, Inc. |
Dock-and-lock (DNL) complexes for delivery of interference RNA
|
|
US8551480B2
(en)
|
2004-02-13 |
2013-10-08 |
Immunomedics, Inc. |
Compositions and methods of use of immunotoxins comprising ranpirnase (Rap) show potent cytotoxic activity
|
|
US20110064754A1
(en)
*
|
2005-03-03 |
2011-03-17 |
Center For Molecular Medicine And Immunology |
Immunoconjugates Comprising Poxvirus-Derived Peptides and Antibodies Against Antigen-Presenting Cells for Subunit-Based Poxvirus Vaccines
|
|
US8562988B2
(en)
|
2005-10-19 |
2013-10-22 |
Ibc Pharmaceuticals, Inc. |
Strategies for improved cancer vaccines
|
|
US9550838B2
(en)
|
2004-02-13 |
2017-01-24 |
Ibc Pharmaceuticals, Inc. |
Dock-and-lock (DNL) complexes for therapeutic and diagnostic use
|
|
US20110020273A1
(en)
*
|
2005-04-06 |
2011-01-27 |
Ibc Pharmaceuticals, Inc. |
Bispecific Immunocytokine Dock-and-Lock (DNL) Complexes and Therapeutic Use Thereof
|
|
US8003111B2
(en)
|
2005-04-06 |
2011-08-23 |
Ibc Pharmaceuticals, Inc. |
Dimeric alpha interferon pegylated site-specifically shows enhanced and prolonged efficacy in vivo
|
|
US8652484B2
(en)
|
2004-02-13 |
2014-02-18 |
Immunomedics, Inc. |
Delivery system for cytotoxic drugs by bispecific antibody pretargeting
|
|
US8435539B2
(en)
|
2004-02-13 |
2013-05-07 |
Immunomedics, Inc. |
Delivery system for cytotoxic drugs by bispecific antibody pretargeting
|
|
US8883160B2
(en)
*
|
2004-02-13 |
2014-11-11 |
Ibc Pharmaceuticals, Inc. |
Dock-and-lock (DNL) complexes for therapeutic and diagnostic use
|
|
US7878978B2
(en)
|
2004-03-18 |
2011-02-01 |
University Of Pittsburgh- Of The Commonwealth System Of Higher Education |
Use of relaxin to increase arterial compliance
|
|
EP1749212A2
(en)
*
|
2004-04-23 |
2007-02-07 |
The University Of Georgia Research Foundation, Inc. |
Diagnostic assay for trypanosoma cruzi infection
|
|
US20160355591A1
(en)
|
2011-05-02 |
2016-12-08 |
Immunomedics, Inc. |
Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies
|
|
JP5214252B2
(ja)
|
2005-03-03 |
2013-06-19 |
イミューノメディクス、インコーポレイテッド |
ヒト化ｌ２４３抗体
|
|
US10058621B2
(en)
|
2015-06-25 |
2018-08-28 |
Immunomedics, Inc. |
Combination therapy with anti-HLA-DR antibodies and kinase inhibitors in hematopoietic cancers
|
|
AU2006232920B2
(en)
*
|
2005-04-06 |
2011-09-29 |
Ibc Pharmaceuticals, Inc. |
Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses
|
|
US8475794B2
(en)
|
2005-04-06 |
2013-07-02 |
Ibc Pharmaceuticals, Inc. |
Combination therapy with anti-CD74 antibodies provides enhanced toxicity to malignancies, Autoimmune disease and other diseases
|
|
US8067006B2
(en)
|
2005-04-06 |
2011-11-29 |
Immunomedics, Inc. |
Polymeric carriers of therapeutic agents and recognition moieties for antibody-based targeting of disease sites
|
|
US8481041B2
(en)
|
2005-04-06 |
2013-07-09 |
Ibc Pharmaceuticals, Inc. |
Dock-and-lock (DNL) constructs for human immunodeficiency virus (HIV) therapy
|
|
US8349332B2
(en)
|
2005-04-06 |
2013-01-08 |
Ibc Pharmaceuticals, Inc. |
Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to B-cell lymphomas and other diseases
|
|
US9623115B2
(en)
|
2005-04-06 |
2017-04-18 |
Ibc Pharmaceuticals, Inc. |
Dock-and-Lock (DNL) Complexes for Disease Therapy
|
|
US8158129B2
(en)
|
2005-04-06 |
2012-04-17 |
Ibc Pharmaceuticals, Inc. |
Dimeric alpha interferon PEGylated site-specifically shows enhanced and prolonged efficacy in vivo
|
|
US9931413B2
(en)
|
2005-04-06 |
2018-04-03 |
Ibc Pharmaceuticals, Inc. |
Tetrameric cytokines with improved biological activity
|
|
PL1874821T3
(pl)
|
2005-04-26 |
2013-09-30 |
Trion Pharma Gmbh |
Kombinacja przeciwciał i glikokortykoidów do leczenia raka
|
|
US7780969B2
(en)
*
|
2005-07-15 |
2010-08-24 |
University Of Georgia Research Foundation, Inc. |
Trypanosoma cruzi proteome compositions and methods
|
|
US20090042235A1
(en)
*
|
2005-08-19 |
2009-02-12 |
Shun Hirota |
Photoregulated peptide, and method for regulation of peptide-protein complex formation using the photoregulated peptide
|
|
US8883162B2
(en)
|
2005-10-19 |
2014-11-11 |
Ibc Pharmaceuticals, Inc. |
Multivalent antibody complexes targeting IGF-1R show potent toxicity against solid tumors
|
|
AU2006302848C1
(en)
*
|
2005-10-19 |
2012-08-02 |
Ibc Pharmaceuticals, Inc. |
Methods and compositions for generating bioactive assemblies of increased complexity and uses
|
|
US9862770B2
(en)
|
2005-10-19 |
2018-01-09 |
Ibc Pharmaceuticals, Inc. |
Multivalent antibody complexes targeting IGF-1R show potent toxicity against solid tumors
|
|
US20100226884A1
(en)
|
2009-01-20 |
2010-09-09 |
Immunomedics, Inc. |
Novel Class of Monospecific and Bispecific Humanized Antibodies that Target the Insulin-like Growth Factor Type I Receptor (IGF-1R)
|
|
JP5090366B2
(ja)
*
|
2005-12-16 |
2012-12-05 |
アイビーシー ファーマスーティカルズ，インク． |
多価イムノグロブリン系生物活性アセンブリー
|
|
US20090110680A1
(en)
*
|
2006-04-07 |
2009-04-30 |
Stephanie Sieger |
Combination of an anti ED-B fibronectin domain antibody and gemcitabine
|
|
EP2015775B1
(en)
*
|
2006-05-03 |
2011-06-01 |
Bayer Schering Pharma Aktiengesellschaft |
Combination of an anti edb fibronectin domain antibody l19-sip and an anti-egfr antibody
|
|
US20100069815A1
(en)
|
2006-06-27 |
2010-03-18 |
Asahi Kasei Kabushiki Kaisha |
Substrate for biological fluid treatment
|
|
WO2012024223A2
(en)
*
|
2010-08-17 |
2012-02-23 |
Immunomedics, Inc. |
Combination therapy with anti-cd74 antibodies provides enhanced toxicity to malignancies, autoimmune disease and other diseases
|
|
US8398956B2
(en)
|
2007-01-11 |
2013-03-19 |
Immunomedics, Inc. |
In vivo copper-free click chemistry for delivery of therapeutic and/or diagnostic agents
|
|
US8889100B2
(en)
|
2007-01-11 |
2014-11-18 |
Immunomedics, Inc. |
Methods and compositions for improved F-18 labeling of proteins, peptides and other molecules
|
|
US8153100B2
(en)
*
|
2007-01-11 |
2012-04-10 |
Immunomedics, Inc. |
Methods and compositions for F-18 labeling of proteins, peptides and other molecules
|
|
US8545809B2
(en)
|
2007-01-11 |
2013-10-01 |
Immunomedics, Inc. |
Methods and compositions for improved 18F labeling of proteins, peptides and other molecules
|
|
US8709382B2
(en)
|
2007-01-11 |
2014-04-29 |
Immunomedics, Inc. |
Methods and compositions for improved F-18 labeling of proteins, peptides and other molecules
|
|
CA2916671C
(en)
*
|
2007-01-17 |
2018-01-09 |
Immunomedics, Inc. |
Polymeric carriers of therapeutic agents and recognition moieties for antibody-based targeting of disease sites
|
|
TWI422594B
(zh)
|
2007-02-02 |
2014-01-11 |
Baylor Res Inst |
經由樹狀細胞去唾液酸糖蛋白受體（ｄｃ-ａｓｇｐｒ）接合抗原呈現細胞之藥劑
|
|
US7786267B2
(en)
*
|
2007-02-02 |
2010-08-31 |
Baylor Research Institute |
Multivariable antigens complexed with targeting humanized monoclonal antibody
|
|
WO2008137120A1
(en)
*
|
2007-05-03 |
2008-11-13 |
Tethys Bioscience, Inc. |
Binding reagents that contain small epitope binding molecules
|
|
JP5263805B2
(ja)
*
|
2007-06-13 |
2013-08-14 |
国立大学法人群馬大学 |
両親媒性の高分子配位子によって安定化された高分子錯体および検査用組成物および医薬組成物
|
|
CA2700000A1
(en)
*
|
2007-07-30 |
2009-02-05 |
Rick L. Tarleton |
Diagnostic assay for trypanosoma cruzi infection
|
|
MX2010003099A
(es)
*
|
2007-09-21 |
2010-05-17 |
Univ California |
Interferon de objetivo demuestra actividades potentes apoptoticas y antitumorales.
|
|
CA2708221C
(en)
*
|
2007-12-06 |
2017-07-25 |
Wayne A. Marasco |
Antibodies against influenza virus and methods of use thereof
|
|
WO2009087474A2
(en)
|
2008-01-08 |
2009-07-16 |
Akthelia Pharmaceuticals |
Agonists for antimicrobial peptide systems
|
|
CA2712505C
(en)
*
|
2008-01-17 |
2018-10-23 |
Fox Chase Cancer Center |
Biomarkers for the diagnosis and treatment of pancreatic cancer
|
|
US8034396B2
(en)
|
2008-04-01 |
2011-10-11 |
Tyco Healthcare Group Lp |
Bioadhesive composition formed using click chemistry
|
|
US9272029B2
(en)
|
2009-03-26 |
2016-03-01 |
Ibc Pharmaceuticals, Inc. |
Interferon lambada-antibody complexes
|
|
BRPI0910482A2
(pt)
*
|
2008-04-29 |
2019-09-24 |
Abbott Lab |
imunoglobinas de domínio variável duplo e usos das mesmas
|
|
CN102026656A
(zh)
*
|
2008-05-16 |
2011-04-20 |
科尔泰拉公司 |
促进伤口愈合的方法
|
|
US20090285757A1
(en)
*
|
2008-05-16 |
2009-11-19 |
Northeastern University |
Methods of targeting cells for diagnosis and therapy
|
|
EP2297209A4
(en)
|
2008-06-03 |
2012-08-01 |
Abbott Lab |
IMMUNOGLOBULINS WITH TWO VARIABLE DOMAINS AND USES THEREOF
|
|
AU2009256246B2
(en)
|
2008-06-03 |
2013-07-18 |
Abbvie Inc. |
Dual variable domain immunoglobulins and uses thereof
|
|
AU2009254501B2
(en)
|
2008-06-05 |
2014-07-31 |
Ablynx N.V. |
Amino acid sequences directed against envelope proteins of a virus and polypeptides comprising the same for the treatment of viral diseases
|
|
AU2009256547B2
(en)
|
2008-06-13 |
2014-07-10 |
Proyecto De Biomedicina Cima, S.L. |
Apo-A conjugates for the administration of biologically active compounds
|
|
BRPI0915448A2
(pt)
|
2008-07-08 |
2015-11-10 |
Abbott Lab |
imunoglobulinas de domínio variável duplo para prostaglandina e2 e usos das mesmas
|
|
CA2734265C
(en)
*
|
2008-08-20 |
2017-12-19 |
Ibc Pharmaceuticals, Inc. |
Dock-and-lock (dnl) vaccines for cancer therapy
|
|
CA2737241C
(en)
*
|
2008-09-26 |
2017-08-29 |
Ucb Pharma S.A. |
Multivalent antibody fusion proteins
|
|
US20110174064A1
(en)
*
|
2008-10-02 |
2011-07-21 |
Ramot At Tel-Aviv University Ltd. |
Method and system for emitting light
|
|
AU2009323996A1
(en)
|
2008-12-03 |
2011-07-07 |
Institut Pasteur |
Use of phenol-soluble modulins for vaccine development
|
|
US9125949B2
(en)
*
|
2008-12-30 |
2015-09-08 |
University Of North Texas |
Direct utilization of plasma proteins for the in vivo assembly of protein-drug/imaging agent conjugates, nanocarriers and coatings for biomaterials
|
|
EP2395085B1
(en)
*
|
2009-02-04 |
2015-06-10 |
Sungkyunkwan University Foundation for Corporate Collaboration |
Small interference rna complex with increased intracellular transmission capacity
|
|
CA2749501C
(en)
|
2009-02-13 |
2017-01-10 |
Immunomedics, Inc. |
Immunoconjugates with an intracellularly-cleavable linkage
|
|
US8648144B2
(en)
|
2009-02-21 |
2014-02-11 |
Sofradim Production |
Crosslinked fibers and method of making same by extrusion
|
|
US8968733B2
(en)
|
2009-02-21 |
2015-03-03 |
Sofradim Production |
Functionalized surgical adhesives
|
|
WO2010095045A1
(en)
|
2009-02-21 |
2010-08-26 |
Sofradim Production |
Amphiphilic compounds and self-assembling compositions made therefrom
|
|
US8535477B2
(en)
|
2009-02-21 |
2013-09-17 |
Sofradim Production |
Medical devices incorporating functional adhesives
|
|
AU2010215199B2
(en)
|
2009-02-21 |
2015-01-15 |
Sofradim Production |
Compounds and medical devices activated with solvophobic linkers
|
|
CA2753173C
(en)
|
2009-02-21 |
2017-05-30 |
Sofradim Production |
Medical devices with an activated coating
|
|
WO2010095053A2
(en)
|
2009-02-21 |
2010-08-26 |
Sofradim Production |
Apparatus and method of reaching polymers by exposure to uv radiation to produce injectable medical devices
|
|
US8877170B2
(en)
|
2009-02-21 |
2014-11-04 |
Sofradim Production |
Medical device with inflammatory response-reducing coating
|
|
EP2398943B1
(en)
|
2009-02-21 |
2013-04-17 |
Sofradim Production |
Crosslinked fibers and method of making same using uv radiation
|
|
US8512728B2
(en)
|
2009-02-21 |
2013-08-20 |
Sofradim Production |
Method of forming a medical device on biological tissue
|
|
EP2398523B1
(en)
|
2009-02-21 |
2018-04-04 |
Covidien LP |
Medical devices having activated surfaces
|
|
WO2010095047A2
(en)
|
2009-02-21 |
2010-08-26 |
Sofradim Production |
Apparatus and method of reacting polymers passing through metal ion chelated resin matrix to produce injectable medical devices
|
|
US8663689B2
(en)
|
2009-02-21 |
2014-03-04 |
Sofradim Production |
Functionalized adhesive medical gel
|
|
US8968818B2
(en)
|
2009-02-21 |
2015-03-03 |
Covidien Lp |
Medical devices having activated surfaces
|
|
US8637074B2
(en)
*
|
2009-03-31 |
2014-01-28 |
Aphios Corporation |
Methods for co-encapsulation of combination drugs and co-encapsulated combination drug product
|
|
EP2258398A1
(en)
|
2009-05-26 |
2010-12-08 |
Araclón Biotech, S. L. |
Albumin-amyloid peptide conjugates and uses thereof
|
|
PL2438087T3
(pl)
*
|
2009-06-05 |
2017-10-31 |
Ablynx Nv |
Triwalentne konstrukty nanociał przeciwko ludzkiemu syncytialnemu wirusowi oddechowemu (hRSV) do zapobiegania i/lub leczenia zakażeń dróg oddechowych
|
|
EP2473187A4
(en)
*
|
2009-08-31 |
2015-09-16 |
Immunomedics Inc |
COMPOSITIONS AND METHODS FOR USE OF IMMUNOXINS WITH RANPIRNASE (RAP) WITH HIGH CYTOTOXIC ACTIVITY
|
|
JP2013503607A
(ja)
*
|
2009-09-01 |
2013-02-04 |
アボット・ラボラトリーズ |
二重可変ドメイン免疫グロブリンおよびその使用
|
|
WO2011029980A1
(es)
|
2009-09-11 |
2011-03-17 |
Proyecto De Biomedicina Cima, S.L. |
Composiciones terapéuticas para el tratamiento de enfermedades causadas por hpv
|
|
EP2478110B1
(en)
|
2009-09-16 |
2016-01-06 |
Immunomedics, Inc. |
Class i anti-cea antibodies and uses thereof
|
|
MX2012004415A
(es)
*
|
2009-10-15 |
2012-05-08 |
Abbott Lab |
Inmunoglobulinas de dominio variable doble y usos de las mismas.
|
|
WO2011050263A2
(en)
*
|
2009-10-23 |
2011-04-28 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Systemic immunosuppression in the treatment of age related macular degeneration and diabetic retinopathy
|
|
UY32979A
(es)
|
2009-10-28 |
2011-02-28 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
|
CA2776563A1
(en)
*
|
2009-11-05 |
2011-05-12 |
Center For Molecular Medicine And Immunology |
Immunoconjugates comprising poxvirus-derived peptides and antibodies against antigen-presenting cells for subunit-based poxvirus vaccines
|
|
CN101876658B
(zh)
*
|
2009-11-25 |
2013-08-28 |
华中科技大学 |
一种具有多价效应和纳米尺寸效应的多肽荧光探针的构建方法及其应用
|
|
EP2507262A1
(en)
|
2009-11-30 |
2012-10-10 |
Ablynx N.V. |
Improved amino acid sequences directed against human respiratory syncytial virus (hrsv) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections
|
|
CA2782194C
(en)
|
2009-12-02 |
2018-01-16 |
Immunomedics, Inc. |
Combination of radiolabelled antibodies (rait) and antibody-drug conjugates (adc) for treatment of pancreatic cancer
|
|
DK2506840T3
(da)
|
2009-12-04 |
2021-04-12 |
Oncoc4 Inc |
Anvendelser af hæmmere af hypoksi-fremkaldende faktorer
|
|
AU2010326004B2
(en)
*
|
2009-12-04 |
2016-04-21 |
Immunomedics, Inc. |
Methods and compositions for improved F-18 labeling of proteins, peptides and other molecules
|
|
EP2509630A4
(en)
*
|
2009-12-09 |
2013-07-17 |
Immunomedics Inc |
SYSTEM FOR PROCESSING CYTOTOXIC REMEDIES THROUGH BISPECIFIC ANTIBODY TARGET
|
|
AU2009356549B2
(en)
*
|
2009-12-15 |
2012-12-06 |
Muhyeon Choe |
Method for manufacturing dimers and multimers in complexes of multiple monomers and repeat chains of affinity domains binding specifically to monomers with increasing the formation of inter-monomeric bond bridges among monomers
|
|
WO2011085354A1
(en)
*
|
2010-01-11 |
2011-07-14 |
Center For Molecular Medicine And Immunology |
Enhanced cytotoxicity of anti-cd74 and anti-hla-dr antibodies with interferon-gamma
|
|
WO2011101332A1
(en)
|
2010-02-16 |
2011-08-25 |
Proyecto De Biomedicina Cima, S.L. |
Compositions based on the fibronectin extracellular domain a for the treatment of melanoma
|
|
EP2550031B1
(en)
|
2010-03-25 |
2015-08-19 |
Sofradim Production |
Medical devices incorporating functional adhesives
|
|
WO2011117745A2
(en)
|
2010-03-25 |
2011-09-29 |
Sofradim Production |
Surgical fasteners and methods for sealing wounds
|
|
AU2011235328A1
(en)
*
|
2010-04-01 |
2012-09-27 |
Immunomedics, Inc. |
Antibody-based depletion of antigen-presenting cells and dendritic cells
|
|
EP2588525A4
(en)
|
2010-06-29 |
2015-06-10 |
Covidien Lp |
MICROWAVE POWERED REACTOR AND IN SITU IMPLANT TRAINING METHOD
|
|
US8865857B2
(en)
|
2010-07-01 |
2014-10-21 |
Sofradim Production |
Medical device with predefined activated cellular integration
|
|
AU2011284449B2
(en)
|
2010-07-27 |
2015-07-23 |
Sofradim Production |
Polymeric fibers having tissue reactive members
|
|
JP2013537415A
(ja)
|
2010-08-03 |
2013-10-03 |
アッヴィ・インコーポレイテッド |
二重可変ドメイン免疫グロブリンおよびその使用
|
|
CN103260639A
(zh)
|
2010-08-26 |
2013-08-21 |
Abbvie公司 |
双重可变结构域免疫球蛋白及其用途
|
|
TW201302793A
(zh)
|
2010-09-03 |
2013-01-16 |
Glaxo Group Ltd |
新穎之抗原結合蛋白
|
|
EP2623119B1
(en)
|
2010-09-30 |
2017-06-14 |
Riken |
Drug used in glioma treatment method, glioma examination method, method of delivering a desired material to a glioma
|
|
AU2011323354B2
(en)
*
|
2010-11-03 |
2014-07-31 |
Ibc Pharmaceuticals, Inc. |
Dock-and-lock (DNL) constructs for human immunodeficiency virus (HIV) therapy
|
|
WO2012123269A1
(en)
|
2011-03-11 |
2012-09-20 |
Proyecto De Biomedicina Cima, S.L. |
Immunogenic compositions and methods for their use
|
|
EP2505640A1
(en)
|
2011-03-29 |
2012-10-03 |
Neo Virnatech, S.L. |
Vaccine compositions for birnavirus-borne diseases
|
|
EP2704751B1
(en)
|
2011-05-02 |
2019-04-17 |
Immunomedics, Inc. |
Ultrafiltration concentration of allotype selected antibodies for small-volume administration
|
|
WO2012162583A1
(en)
*
|
2011-05-26 |
2012-11-29 |
Ibc Pharmaceuticals, Inc. |
Design and construction of novel multivalent antibodies
|
|
EP2729488A4
(en)
*
|
2011-07-06 |
2015-01-14 |
Medimmune Llc |
PROCESS FOR PREPARING MULTIMANT POLYPEPTIDES
|
|
US20130058947A1
(en)
|
2011-09-02 |
2013-03-07 |
Stem Centrx, Inc |
Novel Modulators and Methods of Use
|
|
EP2606897A1
(en)
|
2011-12-22 |
2013-06-26 |
Laboratorios Del. Dr. Esteve, S.A. |
Methods and compositions for the treatment of diseases caused by enveloped viruses
|
|
UY34558A
(es)
|
2011-12-30 |
2013-07-31 |
Abbvie Inc |
Proteínas de unión específicas duales dirigidas contra il-13 y/o il-17
|
|
CN102559636B
(zh)
*
|
2011-12-30 |
2014-03-12 |
百泰生物药业有限公司 |
用于白血病和自身免疫疾病的抗体融合蛋白及其制备方法
|
|
CN104363919A
(zh)
|
2012-06-01 |
2015-02-18 |
Ibc药品公司 |
具有改进的体内稳定性、药物代谢动力学和功效的多聚体复合物
|
|
WO2013188740A1
(en)
|
2012-06-14 |
2013-12-19 |
Ambrx, Inc. |
Anti-psma antibodies conjugated to nuclear receptor ligand polypeptides
|
|
US10131712B2
(en)
|
2012-08-14 |
2018-11-20 |
Ibc Pharmaceuticals, Inc. |
Combination therapy with T-cell redirecting bispecific antibodies and checkpoint inhibitors
|
|
US9382329B2
(en)
|
2012-08-14 |
2016-07-05 |
Ibc Pharmaceuticals, Inc. |
Disease therapy by inducing immune response to Trop-2 expressing cells
|
|
US20150231241A1
(en)
|
2012-08-14 |
2015-08-20 |
Ibc Pharmaceuticals, Inc. |
Combination therapy for inducing immune response to disease
|
|
US9682143B2
(en)
|
2012-08-14 |
2017-06-20 |
Ibc Pharmaceuticals, Inc. |
Combination therapy for inducing immune response to disease
|
|
WO2014028560A2
(en)
|
2012-08-14 |
2014-02-20 |
Ibc Pharmaceuticals, Inc. |
T-cell redirecting bispecific antibodies for treatment of disease
|
|
KR20210111353A
(ko)
|
2012-11-01 |
2021-09-10 |
애브비 인코포레이티드 |
항-ｖｅｇｆ／ｄｌｌ4 이원 가변 도메인 면역글로불린 및 이의 용도
|
|
US9803021B2
(en)
|
2012-12-07 |
2017-10-31 |
The Regents Of The University Of California |
CD138-targeted interferon demonstrates potent apoptotic and anti-tumor activities
|
|
CA2884313C
(en)
|
2012-12-13 |
2023-01-03 |
Immunomedics, Inc. |
Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
|
|
JP2016509014A
(ja)
|
2013-02-08 |
2016-03-24 |
ステムセントリックス， インコーポレイテッド |
新規の多特異的構成物
|
|
WO2014143383A1
(en)
|
2013-03-13 |
2014-09-18 |
Agilent Technologies, Inc. |
Transposome tethered to a gene delivery vehicle
|
|
AU2014227732A1
(en)
|
2013-03-15 |
2015-09-17 |
Abbvie Inc. |
Dual specific binding proteins directed against IL-1 beta and IL-17
|
|
US9802995B2
(en)
|
2013-03-15 |
2017-10-31 |
Memorial Sloan-Kettering Cancer Center |
Antibody multimerization technologies
|
|
US10093745B2
(en)
|
2013-05-29 |
2018-10-09 |
The Regents Of The University Of California |
Anti-CSPG4 fusions with interferon for the treatment of malignancy
|
|
US9775928B2
(en)
|
2013-06-18 |
2017-10-03 |
Covidien Lp |
Adhesive barbed filament
|
|
CN104650237B
(zh)
*
|
2013-06-28 |
2019-08-20 |
英科隆生物技术（杭州）有限公司 |
一种交联抗体及其在免疫检测中应用
|
|
CN103382224B
(zh)
*
|
2013-06-28 |
2015-03-18 |
英科隆生物技术（杭州）有限公司 |
含有四聚体形式的异源交联抗体的异源交联物及其应用
|
|
US9416197B2
(en)
|
2013-11-01 |
2016-08-16 |
Ibc Pharmaceuticals, Inc. |
Bispecific antibodies that neutralize both TNF-α and IL-6: novel therapeutic agent for autoimmune disease
|
|
CN103897064B
(zh)
*
|
2013-11-29 |
2016-05-11 |
广州优联康医药科技有限公司 |
长效重组人绒促性素融合蛋白
|
|
JOP20200094A1
(ar)
|
2014-01-24 |
2017-06-16 |
Dana Farber Cancer Inst Inc |
جزيئات جسم مضاد لـ pd-1 واستخداماتها
|
|
JOP20200096A1
(ar)
|
2014-01-31 |
2017-06-16 |
Children’S Medical Center Corp |
جزيئات جسم مضاد لـ tim-3 واستخداماتها
|
|
US11039621B2
(en)
|
2014-02-19 |
2021-06-22 |
Corning Incorporated |
Antimicrobial glass compositions, glasses and polymeric articles incorporating the same
|
|
US9622483B2
(en)
|
2014-02-19 |
2017-04-18 |
Corning Incorporated |
Antimicrobial glass compositions, glasses and polymeric articles incorporating the same
|
|
US11039620B2
(en)
|
2014-02-19 |
2021-06-22 |
Corning Incorporated |
Antimicrobial glass compositions, glasses and polymeric articles incorporating the same
|
|
CN106132436B
(zh)
|
2014-02-21 |
2021-06-15 |
Ibc药品公司 |
通过诱导对trop-2表达细胞的免疫应答的疾病疗法
|
|
EP3110445A4
(en)
|
2014-02-25 |
2017-09-27 |
Immunomedics, Inc. |
Humanized rfb4 anti-cd22 antibody
|
|
WO2015138638A1
(en)
|
2014-03-11 |
2015-09-17 |
Theraly Pharmaceuticals, Inc. |
Long acting trail receptor agonists for treatment of autoimmune diseases
|
|
UY36032A
(es)
|
2014-03-14 |
2015-10-30 |
Novartis Ag |
Moléculas de anticuerpo que se unen a lag-3 y usos de las mismas
|
|
US20170335281A1
(en)
|
2014-03-15 |
2017-11-23 |
Novartis Ag |
Treatment of cancer using chimeric antigen receptor
|
|
AU2015258875B2
(en)
|
2014-05-16 |
2020-12-24 |
Baylor Research Institute |
Methods and compositions for treating autoimmune and inflammatory conditions
|
|
CN113549153A
(zh)
|
2014-05-29 |
2021-10-26 |
宏观基因有限公司 |
三特异性结合分子和其使用方法
|
|
WO2015200260A1
(en)
|
2014-06-24 |
2015-12-30 |
Immunomedics, Inc. |
Anti-histone therapy for vascular necrosis in severe glomerulonephritis
|
|
WO2016014553A1
(en)
|
2014-07-21 |
2016-01-28 |
Novartis Ag |
Sortase synthesized chimeric antigen receptors
|
|
EP3193915A1
(en)
|
2014-07-21 |
2017-07-26 |
Novartis AG |
Combinations of low, immune enhancing. doses of mtor inhibitors and cars
|
|
KR102612313B1
(ko)
|
2014-07-21 |
2023-12-12 |
노파르티스 아게 |
인간화 항-bcma 키메라 항원 수용체를 사용한 암의 치료
|
|
US9777061B2
(en)
|
2014-07-21 |
2017-10-03 |
Novartis Ag |
Treatment of cancer using a CD33 chimeric antigen receptor
|
|
EP4205749A1
(en)
|
2014-07-31 |
2023-07-05 |
Novartis AG |
Subset-optimized chimeric antigen receptor-containing cells
|
|
US10851149B2
(en)
|
2014-08-14 |
2020-12-01 |
The Trustees Of The University Of Pennsylvania |
Treatment of cancer using GFR α-4 chimeric antigen receptor
|
|
WO2016028896A1
(en)
|
2014-08-19 |
2016-02-25 |
Novartis Ag |
Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment
|
|
BR112017005390A2
(pt)
|
2014-09-17 |
2017-12-12 |
Novartis Ag |
células citotóxicas alvo com receptores quiméricos para imunoterapia adotiva
|
|
JP6678941B2
(ja)
|
2014-10-07 |
2020-04-15 |
イミューノメディクス、インコーポレイテッドＩｍｍｕｎｏｍｅｄｉｃｓ， Ｉｎｃ． |
抗体−薬物コンジュゲートのネオアジュバント使用
|
|
EA201790834A1
(ru)
|
2014-10-14 |
2018-01-31 |
Новартис Аг |
Молекулы антител к pd-l1 и их применение
|
|
US20180334490A1
(en)
|
2014-12-03 |
2018-11-22 |
Qilong H. Wu |
Methods for b cell preconditioning in car therapy
|
|
WO2016094881A2
(en)
|
2014-12-11 |
2016-06-16 |
Abbvie Inc. |
Lrp-8 binding proteins
|
|
US11426468B2
(en)
*
|
2014-12-19 |
2022-08-30 |
Ablynx N.V. |
Cysteine linked nanobody dimers
|
|
RU2017129236A
(ru)
|
2015-01-26 |
2019-03-07 |
Макродженикс, Инк. |
Мультивалентные молекулы, содержащие dr5-связывающие домены
|
|
US11304976B2
(en)
|
2015-02-18 |
2022-04-19 |
Enlivex Therapeutics Ltd |
Combination immune therapy and cytokine control therapy for cancer treatment
|
|
US11596652B2
(en)
|
2015-02-18 |
2023-03-07 |
Enlivex Therapeutics R&D Ltd |
Early apoptotic cells for use in treating sepsis
|
|
US11318163B2
(en)
|
2015-02-18 |
2022-05-03 |
Enlivex Therapeutics Ltd |
Combination immune therapy and cytokine control therapy for cancer treatment
|
|
IL297418B2
(en)
|
2015-02-18 |
2023-11-01 |
Enlivex Therapeutics Rdo Ltd |
Combined immunotherapy and cytokine control therapy for cancer treatment
|
|
US11497767B2
(en)
|
2015-02-18 |
2022-11-15 |
Enlivex Therapeutics R&D Ltd |
Combination immune therapy and cytokine control therapy for cancer treatment
|
|
US11000548B2
(en)
|
2015-02-18 |
2021-05-11 |
Enlivex Therapeutics Ltd |
Combination immune therapy and cytokine control therapy for cancer treatment
|
|
HRP20220893T1
(hr)
|
2015-04-08 |
2022-10-14 |
Novartis Ag |
Cd20 terapije, cd22 terapije, i kombinirane terapije sa stanicom koja eksprimira cd19 kimerni antigenski receptor
|
|
AU2016250570B2
(en)
|
2015-04-21 |
2021-07-01 |
Enlivex Therapeutics Rdo Ltd |
Therapeutic pooled blood apoptotic cell preparations and uses thereof
|
|
WO2016172427A1
(en)
|
2015-04-22 |
2016-10-27 |
Immunomedics, Inc. |
Isolation, detection, diagnosis and/or characterization of circulating trop-2-positive cancer cells
|
|
WO2016172583A1
(en)
|
2015-04-23 |
2016-10-27 |
Novartis Ag |
Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
|
|
WO2016191481A1
(en)
|
2015-05-28 |
2016-12-01 |
Immunomedics, Inc. |
T20 constructs for anti-hiv (human immunodeficiency virus) therapy and/or vaccines
|
|
TWI773646B
(zh)
|
2015-06-08 |
2022-08-11 |
美商宏觀基因股份有限公司 |
結合lag-3的分子和其使用方法
|
|
TW201710286A
(zh)
|
2015-06-15 |
2017-03-16 |
艾伯維有限公司 |
抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
|
|
SI3313443T1
(sl)
|
2015-06-25 |
2023-11-30 |
Immunomedics, Inc. |
Kombiniranje protiteles proti HLA-DR ali proti TROP-2 z zaviralci mikrotubulov, zaviralci PARP, zaviralci brutonove kinaze ali zaviralci fosfoinozitid 3-kinaze pomembno izboljša izid zdravljenja pri raku
|
|
EP3316885B1
(en)
|
2015-07-01 |
2021-06-23 |
Immunomedics, Inc. |
Antibody-sn-38 immunoconjugates with a cl2a linker
|
|
EP3322716B1
(en)
*
|
2015-07-15 |
2025-02-12 |
California Institute of Technology |
Il-17f-specific capture agents and methods of using
|
|
US20180207273A1
(en)
|
2015-07-29 |
2018-07-26 |
Novartis Ag |
Combination therapies comprising antibody molecules to tim-3
|
|
CN108025051B
(zh)
|
2015-07-29 |
2021-12-24 |
诺华股份有限公司 |
包含抗pd-1抗体分子的联合疗法
|
|
HUE055469T2
(hu)
|
2015-07-29 |
2021-11-29 |
Novartis Ag |
A LAG-3 elleni antitest molekulákat tartalmazó kombinált terápiák
|
|
SMT202100527T1
(it)
|
2015-07-30 |
2021-11-12 |
Macrogenics Inc |
Molecole di legame a pd-1 e lag-3 e loro metodi d'uso
|
|
BR112018006817A2
(pt)
|
2015-10-08 |
2018-10-23 |
Macrogenics Inc |
método de tratamento do câncer
|
|
MX2018007089A
(es)
|
2015-12-14 |
2019-01-30 |
Macrogenics Inc |
Moleculas biespecificas que tienen inmunorreactividad con pd-1 y ctla-4, y metodos de uso de las mismas.
|
|
RU2018125603A
(ru)
|
2015-12-17 |
2020-01-21 |
Новартис Аг |
Комбинация ингибитора с-мет с молекулой антитела к pd-1 и ее применения
|
|
JP2019503349A
(ja)
|
2015-12-17 |
2019-02-07 |
ノバルティス アーゲー |
Ｐｄ−１に対する抗体分子およびその使用
|
|
ES3013312T3
(en)
|
2015-12-17 |
2025-04-11 |
Univ Johns Hopkins |
Ameliorating systemic sclerosis with death receptor agonists
|
|
MA44140A
(fr)
|
2015-12-22 |
2021-05-19 |
Dana Farber Cancer Inst Inc |
Récepteur d'antigène chimérique (car) contre la mésothéline et anticorps contre l'inhibiteur de pd-l1 pour une utilisation combinée dans une thérapie anticancéreuse
|
|
US20210198368A1
(en)
|
2016-01-21 |
2021-07-01 |
Novartis Ag |
Multispecific molecules targeting cll-1
|
|
US20170233472A1
(en)
|
2016-02-17 |
2017-08-17 |
Macrogenics, Inc. |
ROR1-Binding Molecules, and Methods of Use Thereof
|
|
JP6884155B2
(ja)
|
2016-02-18 |
2021-06-09 |
エンリヴェックス セラピューティクス リミテッド |
癌治療のための併用免疫療法及びサイトカイン制御療法
|
|
AU2017225733A1
(en)
|
2016-03-04 |
2018-09-27 |
Novartis Ag |
Cells expressing multiple chimeric antigen receptor (CAR) molecules and uses therefore
|
|
WO2017165683A1
(en)
|
2016-03-23 |
2017-09-28 |
Novartis Ag |
Cell secreted minibodies and uses thereof
|
|
US11084879B2
(en)
|
2016-04-07 |
2021-08-10 |
The Johns Hopkins University |
Compositions and methods for treating pancreatitis and pain with death receptor agonists
|
|
EP3443096B1
(en)
|
2016-04-15 |
2023-03-01 |
Novartis AG |
Compositions and methods for selective expression of chimeric antigen receptors
|
|
MY198114A
(en)
|
2016-04-15 |
2023-08-04 |
Macrogenics Inc |
Novel b7-h3-binding molecules, antibody drug conjugates thereof and methods of use thereof
|
|
US20210177896A1
(en)
|
2016-06-02 |
2021-06-17 |
Novartis Ag |
Therapeutic regimens for chimeric antigen receptor (car)- expressing cells
|
|
KR20190015461A
(ko)
|
2016-06-06 |
2019-02-13 |
노쓰웨스턴유니버시티 |
융합 단백질 작제물
|
|
US10669338B2
(en)
|
2016-06-17 |
2020-06-02 |
Immunomedics, Inc. |
Anti-PD-1 checkpoint inhibitor antibodies that block binding of PD-L1 to PD-1
|
|
SG11201900344YA
(en)
|
2016-07-15 |
2019-02-27 |
Novartis Ag |
Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor
|
|
EP3491016A1
(en)
|
2016-07-28 |
2019-06-05 |
Novartis AG |
Combination therapies of chimeric antigen receptors and pd-1 inhibitors
|
|
AU2017306267A1
(en)
|
2016-08-01 |
2019-02-14 |
Novartis Ag |
Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-M2 macrophage molecule
|
|
WO2018027223A1
(en)
|
2016-08-05 |
2018-02-08 |
Duke University |
Camkk2 inhibitor compositions and methods of using the same
|
|
CN106267191A
(zh)
*
|
2016-09-03 |
2017-01-04 |
山西纳安生物科技有限公司 |
纳米抗体生物药透皮给药制剂系统及制备方法和应用
|
|
CA3039646A1
(en)
|
2016-10-07 |
2018-04-12 |
Novartis Ag |
Chimeric antigen receptors for the treatment of cancer
|
|
JOP20190100A1
(ar)
|
2016-11-19 |
2019-05-01 |
Potenza Therapeutics Inc |
بروتينات ربط مولد ضد مضاد لـ gitr وطرق استخدامها
|
|
KR102630036B1
(ko)
|
2016-12-23 |
2024-01-29 |
마크로제닉스, 인크. |
Adam9-결합 분자, 및 이것의 사용 방법
|
|
EP4043485A1
(en)
|
2017-01-26 |
2022-08-17 |
Novartis AG |
Cd28 compositions and methods for chimeric antigen receptor therapy
|
|
US11459394B2
(en)
|
2017-02-24 |
2022-10-04 |
Macrogenics, Inc. |
Bispecific binding molecules that are capable of binding CD137 and tumor antigens, and uses thereof
|
|
EP3589647A1
(en)
|
2017-02-28 |
2020-01-08 |
Novartis AG |
Shp inhibitor compositions and uses for chimeric antigen receptor therapy
|
|
WO2018162450A1
(en)
|
2017-03-06 |
2018-09-13 |
Fundación Para La Investigación Médica Aplicada |
New inmunostimulatory compositions comprising an entity of cold inducible rna-binding protein with an antigen for the activation of dendritic cells
|
|
WO2018187074A1
(en)
|
2017-04-03 |
2018-10-11 |
Immunomedics, Inc. |
Subcutaneous administration of antibody-drug conjugates for cancer therapy
|
|
PT3615142T
(pt)
*
|
2017-04-24 |
2022-06-28 |
Advanced Accelerator Applications |
Ativador de neutrões acionado por acelerador para braquiterapia
|
|
EP3615055A1
(en)
|
2017-04-28 |
2020-03-04 |
Novartis AG |
Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
|
|
EP3615068A1
(en)
|
2017-04-28 |
2020-03-04 |
Novartis AG |
Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
|
|
WO2018204873A1
(en)
*
|
2017-05-05 |
2018-11-08 |
Memorial Sloan Kettering Cancer Center |
Modular self assembly disassembly (sada) technologies
|
|
MX2019015885A
(es)
|
2017-06-22 |
2020-09-10 |
Novartis Ag |
Moleculas de anticuerpo que se unen a cd73 y usos de las mismas.
|
|
KR20200022447A
(ko)
|
2017-06-27 |
2020-03-03 |
노파르티스 아게 |
항-tim-3 항체의 투여 요법 및 그의 용도
|
|
PE20200757A1
(es)
|
2017-07-11 |
2020-07-27 |
Compass Therapeutics Llc |
Anticuerpos agonistas que se unen a cd137 humano y sus usos
|
|
WO2019018730A1
(en)
|
2017-07-20 |
2019-01-24 |
Novartis Ag |
DOSAGE REGIMES FOR ANTI-LAG3 ANTIBODIES AND USES THEREOF
|
|
TWI635559B
(zh)
*
|
2017-07-25 |
2018-09-11 |
春田科技顧問股份有限公司 |
裝載埠的吹淨裝置及其吹淨方法
|
|
CN111448210B
(zh)
|
2017-07-26 |
2024-05-14 |
四十七公司 |
抗SIRP-α抗体及相关方法
|
|
US11718679B2
(en)
|
2017-10-31 |
2023-08-08 |
Compass Therapeutics Llc |
CD137 antibodies and PD-1 antagonists and uses thereof
|
|
US20200277378A1
(en)
|
2017-11-16 |
2020-09-03 |
Novartis Ag |
Combination therapies
|
|
US11851497B2
(en)
|
2017-11-20 |
2023-12-26 |
Compass Therapeutics Llc |
CD137 antibodies and tumor antigen-targeting antibodies and uses thereof
|
|
KR20200098590A
(ko)
|
2017-12-12 |
2020-08-20 |
마크로제닉스, 인크. |
이중특이적 cd16-결합 분자 및 질환 치료에서의 그것의 용도
|
|
AU2019205330B2
(en)
|
2018-01-04 |
2025-09-11 |
Iconic Therapeutics Llc |
Anti-tissue factor antibodies, antibody-drug conjugates, and related methods
|
|
EP3737692A4
(en)
|
2018-01-09 |
2021-09-29 |
Elstar Therapeutics, Inc. |
CALRETICULIN AND MODIFIED T-LYMPHOCYTES BINDING CONSTRUCTIONS FOR THE TREATMENT OF DISEASES
|
|
EP3746116A1
(en)
|
2018-01-31 |
2020-12-09 |
Novartis AG |
Combination therapy using a chimeric antigen receptor
|
|
TWI786265B
(zh)
*
|
2018-02-02 |
2022-12-11 |
美商再生元醫藥公司 |
用於表徵蛋白質二聚合之系統及方法
|
|
MX2020008489A
(es)
|
2018-02-15 |
2020-09-25 |
Macrogenics Inc |
Dominios de union a cd3 variantes y su uso en terapias de combinacion para el tratamiento de enfermedades.
|
|
US20190269728A1
(en)
|
2018-03-02 |
2019-09-05 |
Sixfold Bioscience Ltd. |
Compositions for delivery of cargo to cells
|
|
EP3765517A1
(en)
|
2018-03-14 |
2021-01-20 |
Elstar Therapeutics, Inc. |
Multifunctional molecules that bind to calreticulin and uses thereof
|
|
JP2021518387A
(ja)
|
2018-03-19 |
2021-08-02 |
バイオヴェンチャーズ リミテッド ライアビリティ カンパニー |
ペリオスチン抗体およびその使用方法
|
|
US20210147547A1
(en)
|
2018-04-13 |
2021-05-20 |
Novartis Ag |
Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof
|
|
WO2019210153A1
(en)
|
2018-04-27 |
2019-10-31 |
Novartis Ag |
Car t cell therapies with enhanced efficacy
|
|
WO2019226658A1
(en)
|
2018-05-21 |
2019-11-28 |
Compass Therapeutics Llc |
Multispecific antigen-binding compositions and methods of use
|
|
CN112384534A
(zh)
|
2018-05-21 |
2021-02-19 |
指南针制药有限责任公司 |
用于增强nk细胞对靶细胞的杀死的组合物和方法
|
|
WO2019227003A1
(en)
|
2018-05-25 |
2019-11-28 |
Novartis Ag |
Combination therapy with chimeric antigen receptor (car) therapies
|
|
WO2019227022A1
(en)
|
2018-05-25 |
2019-11-28 |
Bioventures, Llc |
Myxoma virus compositions and methods of use
|
|
US20210214459A1
(en)
|
2018-05-31 |
2021-07-15 |
Novartis Ag |
Antibody molecules to cd73 and uses thereof
|
|
EP3806962A1
(en)
|
2018-06-13 |
2021-04-21 |
Novartis AG |
Bcma chimeric antigen receptors and uses thereof
|
|
MA52969A
(fr)
|
2018-06-19 |
2021-04-28 |
Atarga Llc |
Molécules d'anticorps se liant au composant du complément 5 et leurs utilisations
|
|
AU2019297451A1
(en)
|
2018-07-03 |
2021-01-28 |
Marengo Therapeutics, Inc. |
Anti-TCR antibody molecules and uses thereof
|
|
AR116109A1
(es)
|
2018-07-10 |
2021-03-31 |
Novartis Ag |
Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
|
|
WO2020021465A1
(en)
|
2018-07-25 |
2020-01-30 |
Advanced Accelerator Applications (Italy) S.R.L. |
Method of treatment of neuroendocrine tumors
|
|
CN112638946A
(zh)
|
2018-08-16 |
2021-04-09 |
坎塔吉亚有限责任公司 |
抗il1rap抗体组合物
|
|
AU2019379576A1
(en)
|
2018-11-13 |
2021-06-03 |
Compass Therapeutics Llc |
Multispecific binding constructs against checkpoint molecules and uses thereof
|
|
WO2020106880A1
(en)
|
2018-11-20 |
2020-05-28 |
Bioventures, Llc |
Cells for the production of viruses and methods of using the same
|
|
WO2020128972A1
(en)
|
2018-12-20 |
2020-06-25 |
Novartis Ag |
Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
|
|
MX2021007391A
(es)
|
2018-12-20 |
2021-09-23 |
Novartis Ag |
Regimenes de baja dosis extendida para inhibidores de mdm2.
|
|
US10871640B2
(en)
|
2019-02-15 |
2020-12-22 |
Perkinelmer Cellular Technologies Germany Gmbh |
Methods and systems for automated imaging of three-dimensional objects
|
|
JP7483732B2
(ja)
|
2019-02-15 |
2024-05-15 |
ノバルティス アーゲー |
３－（１－オキソ－５－（ピペリジン－４－イル）イソインドリン－２－イル）ピペリジン－２，６－ジオン誘導体及びその使用
|
|
ES2982474T3
(es)
|
2019-02-15 |
2024-10-16 |
Novartis Ag |
Derivados de 3-(1-oxoisoindolin-2-il)piperidin-1,6-diona sustituidos y usos de estos
|
|
CA3130754A1
(en)
|
2019-02-21 |
2020-08-27 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to t cell related cancer cells and uses thereof
|
|
WO2020172605A1
(en)
|
2019-02-21 |
2020-08-27 |
Elstar Therapeutics, Inc. |
Antibody molecules that bind to nkp30 and uses thereof
|
|
WO2020172553A1
(en)
|
2019-02-22 |
2020-08-27 |
Novartis Ag |
Combination therapies of egfrviii chimeric antigen receptors and pd-1 inhibitors
|
|
SG11202110732XA
(en)
|
2019-03-29 |
2021-10-28 |
Atarga Llc |
Anti fgf23 antibody
|
|
KR20220038415A
(ko)
|
2019-07-26 |
2022-03-28 |
벤더르빌트 유니버시티 |
엔테로바이러스 d68에 대한 인간 모노클로날 항체
|
|
WO2021030680A1
(en)
|
2019-08-15 |
2021-02-18 |
Regeneron Pharmaceuticals, Inc. |
Multispecific antigen-binding molecules for cell targeting and uses thereof
|
|
EP4021909A4
(en)
|
2019-08-29 |
2023-08-30 |
David C. Martin |
Biofunctional thiophene monomers
|
|
KR20220087498A
(ko)
|
2019-10-21 |
2022-06-24 |
노파르티스 아게 |
Tim-3 억제제 및 그의 용도
|
|
IL292347A
(en)
|
2019-10-21 |
2022-06-01 |
Novartis Ag |
Combination treatments with ventoclax and tim-3 inhibitors
|
|
IL293215A
(en)
|
2019-11-26 |
2022-07-01 |
Novartis Ag |
Chimeric antigen receptors that bind bcma and cd19 and their uses
|
|
JP2023507190A
(ja)
|
2019-12-20 |
2023-02-21 |
ノバルティス アーゲー |
増殖性疾患を治療するための抗ＴＧＦβ抗体及びチェックポイント阻害薬の使用
|
|
GB2609554B
(en)
|
2020-01-03 |
2025-08-20 |
Marengo Therapeutics Inc |
Anti-TCR antibody molecules and uses thereof
|
|
EP4090762A1
(en)
|
2020-01-17 |
2022-11-23 |
Becton, Dickinson and Company |
Methods and compositions for single cell secretomics
|
|
CN114980902A
(zh)
|
2020-01-17 |
2022-08-30 |
诺华股份有限公司 |
用于治疗骨髓增生异常综合征或慢性粒单核细胞白血病的包含tim-3抑制剂和低甲基化药物的组合
|
|
KR20220140568A
(ko)
|
2020-02-11 |
2022-10-18 |
벤더르빌트 유니버시티 |
중증 급성 호흡기 증후군 코로나바이러스 2(SARS-CoV-2)에 대한 인간 단일클론 항체
|
|
US12435155B2
(en)
|
2020-02-21 |
2025-10-07 |
Macrogenics, Inc. |
CD137 binding molecules and uses thereof
|
|
KR20220147109A
(ko)
|
2020-02-27 |
2022-11-02 |
노파르티스 아게 |
키메라 항원 수용체 발현 세포의 제조 방법
|
|
WO2021195385A1
(en)
|
2020-03-26 |
2021-09-30 |
Vanderbilt University |
HUMAN MONOCLONAL ANTIBODIES TO SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-GoV-2)
|
|
MX2022011892A
(es)
|
2020-03-26 |
2022-10-18 |
Univ Vanderbilt |
Anticuerpos monoclonales humanos dirigidos contra el coronavirus 2 del sindrome respiratorio agudo grave (sars-cov-2).
|
|
JP2023523345A
(ja)
|
2020-04-27 |
2023-06-02 |
シックスフォールド バイオサイエンス リミテッド |
モジュール官能基を有する核酸ナノ粒子を含有する組成物
|
|
CN111500586B
(zh)
*
|
2020-05-21 |
2022-11-04 |
昆明理工大学 |
特异结合狂犬病毒l蛋白加帽区的核酸适配体及其应用
|
|
US11767353B2
(en)
|
2020-06-05 |
2023-09-26 |
Theraly Fibrosis, Inc. |
Trail compositions with reduced immunogenicity
|
|
US20230321067A1
(en)
|
2020-06-23 |
2023-10-12 |
Novartis Ag |
Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
|
|
WO2022000136A1
(en)
*
|
2020-06-28 |
2022-01-06 |
Dingfu Biotarget Co., Ltd. |
Methods and compositions for cancer treatment
|
|
EP4175650A1
(en)
|
2020-07-06 |
2023-05-10 |
Kiromic BioPharma, Inc. |
Mesothelin isoform binding molecules and chimeric pd1 receptor molecules, cells containing the same and uses thereof
|
|
TW202216761A
(zh)
|
2020-07-16 |
2022-05-01 |
瑞士商諾華公司 |
抗β細胞素抗體、其片段及多特異性結合分子
|
|
WO2022026592A2
(en)
|
2020-07-28 |
2022-02-03 |
Celltas Bio, Inc. |
Antibody molecules to coronavirus and uses thereof
|
|
EP4188549A1
(en)
|
2020-08-03 |
2023-06-07 |
Novartis AG |
Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
|
US20230338587A1
(en)
|
2020-08-31 |
2023-10-26 |
Advanced Accelerator Applications International Sa |
Method of treating psma-expressing cancers
|
|
WO2022043557A1
(en)
|
2020-08-31 |
2022-03-03 |
Advanced Accelerator Applications International Sa |
Method of treating psma-expressing cancers
|
|
CN112156194B
(zh)
*
|
2020-09-29 |
2023-01-24 |
中国工程物理研究院核物理与化学研究所 |
一种去除177Lu溶液中内毒素的方法
|
|
US20240002509A1
(en)
|
2020-11-06 |
2024-01-04 |
Novartis Ag |
ANTIBODY Fc VARIANTS
|
|
CN116635062A
(zh)
|
2020-11-13 |
2023-08-22 |
诺华股份有限公司 |
使用表达嵌合抗原受体（car）的细胞的组合疗法
|
|
WO2022108627A1
(en)
|
2020-11-18 |
2022-05-27 |
Kiromic Biopharma, Inc.Kiromic Biopharma, Inc. |
Gamma-delta t cell manufacturing processes and chimeric pd1 receptor molecules
|
|
US20240141060A1
(en)
|
2021-01-29 |
2024-05-02 |
Novartis Ag |
Dosage regimes for anti-cd73 and anti-entpd2 antibodies and uses thereof
|
|
TW202304979A
(zh)
|
2021-04-07 |
2023-02-01 |
瑞士商諾華公司 |
抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
|
|
AR125874A1
(es)
|
2021-05-18 |
2023-08-23 |
Novartis Ag |
Terapias de combinación
|
|
CN113403384A
(zh)
*
|
2021-06-22 |
2021-09-17 |
南昌大学 |
动脉粥样硬化生物标志物及其应用
|
|
WO2023044483A2
(en)
|
2021-09-20 |
2023-03-23 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of her2 positive cancer
|
|
WO2023092004A1
(en)
|
2021-11-17 |
2023-05-25 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of tau-related disorders
|
|
US20230383010A1
(en)
|
2022-02-07 |
2023-11-30 |
Visterra, Inc. |
Anti-idiotype antibody molecules and uses thereof
|
|
GB202204813D0
(en)
|
2022-04-01 |
2022-05-18 |
Bradcode Ltd |
Human monoclonal antibodies and methods of use thereof
|
|
US20250295809A1
(en)
|
2022-05-13 |
2025-09-25 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of her2 positive cancer
|
|
TW202435912A
(zh)
|
2022-08-03 |
2024-09-16 |
美商航海家醫療公司 |
用於穿過血腦屏障之組合物及方法
|
|
WO2024168061A2
(en)
|
2023-02-07 |
2024-08-15 |
Ayan Therapeutics Inc. |
Antibody molecules binding to sars-cov-2
|
|
WO2025122634A1
(en)
|
2023-12-05 |
2025-06-12 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of tau-related disorders
|
|
WO2025240781A2
(en)
|
2024-05-15 |
2025-11-20 |
Werewolf Therapeutics, Inc. |
Modified antibodies and immunoglobulin formats
|